Cytokinetics Announces Call for Proposals for Its Sixth Annual Communications Grant Program
28 Setembro 2023 - 8:30AM
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call
for proposals for the sixth annual Cytokinetics Communications
Grant Program. The program will award five grants in the amount of
$20,000 each to patient advocacy organizations serving the
hypertrophic cardiomyopathy (HCM), heart failure and amyotrophic
lateral sclerosis (ALS) communities. The grants are intended to
support increased capacity in communications, awareness building
and community engagement.
“We are proud to continue our tradition of
supporting patient advocacy organizations in their efforts to
prioritize and nurture critical communications and outreach
initiatives,” said Mary Pomerantz, Cytokinetics’ Senior Director of
Patient Advocacy and Engagement. “Over the past five years, our
Communications Grant Program has funded creative and urgently
needed programs that have helped expand patient reach, connect
communities and elevate patient voices. We look forward to
receiving new proposals and once again contributing to the goals
and objectives of patient advocacy organizations.”
The Cytokinetics Communications Grant Program
supports patient advocacy organizations in expanding their reach,
awareness and community engagement by providing resources for new
or crucial communication or outreach initiatives that would
otherwise be challenging to implement. Funding from the
Cytokinetics Communications Grant program may help with
communications programming or personnel, depending on each
organization’s needs. The recipients of the 2023 Cytokinetics
Communications Grants were the HeartBrothers Foundation, The Mended
Hearts, Inc., the Northeast Amyotrophic Lateral Sclerosis
Consortium®, The ALS Association Greater Philadelphia Chapter and
WomenHeart: The National Coalition for Women with Heart
Disease.
Eligible organizations must have nonprofit
organization or registered charity status in the United States,
Canada, Europe or United Kingdom and serve the patient communities
in HCM, heart failure or ALS. Organizations applying for the grant
are required to submit a proposal outlining communication
activities that the funding would support and the potential impact
of the funding. Applications will be evaluated by a committee of
representatives from Cytokinetics based on the proposal’s alignment
with selection criteria. Criteria include reach, awareness,
community engagement and impact. More details can be found at the
application portal listed below. Recipients are responsible for
providing an outcomes report to Cytokinetics to measure the impact
and results of the funding at the end of the year. Applications may
now be submitted online at
https://www.cybergrants.com/Cytokinetics/communications_grant. The
deadline to apply is November 1, 2023, and the grant recipients
will be announced in January 2024. For more information on the
program, including eligibility guidelines, visit
https://cytokinetics.com/responsibility/grants-and-giving/.
About Cytokinetics
Cytokinetics is a late-stage, specialty
cardiovascular biopharmaceutical company focused on discovering,
developing and commercializing first-in-class muscle activators and
next-in-class muscle inhibitors as potential treatments for
debilitating diseases in which cardiac muscle performance is
compromised. As a leader in muscle biology and the mechanics of
muscle performance, the company is developing small molecule drug
candidates specifically engineered to impact myocardial muscle
function and contractility. Aficamten is a next-in-class cardiac
myosin inhibitor, currently the subject of three Phase 3 clinical
trials: SEQUOIA-HCM, evaluating aficamten in patients with
obstructive hypertrophic cardiomyopathy (HCM), MAPLE-HCM,
evaluating aficamten as monotherapy compared to metoprolol as
monotherapy in patients with obstructive HCM and ACACIA-HCM,
evaluating aficamten in patients with non-obstructive HCM.
Cytokinetics is also developing omecamtiv mecarbil, a cardiac
muscle activator in patients with heart failure. Additionally,
Cytokinetics is developing CK-136, a cardiac troponin activator for
the potential treatment HFrEF and other types of heart failure,
such as right ventricular failure, resulting from impaired cardiac
contractility, and CK-586, a cardiac myosin inhibitor with a
mechanism of action distinct from aficamten for the potential
treatment of HFpEF. In 2023, Cytokinetics is celebrating its
25-year history of pioneering innovation in muscle biology and
related pharmacology focused to diseases of muscle dysfunction and
conditions of muscle weakness.
For additional information about Cytokinetics,
visit www.cytokinetics.com and follow us on Twitter, LinkedIn,
Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the “Act”). Cytokinetics disclaims any
intent or obligation to update these forward-looking statements and
claims the protection of the Act’s Safe Harbor for forward-looking
statements. Examples of such statements include, but are not
limited to, statements relating to Cytokinetics’ and its partners’
research and development activities of Cytokinetics’ product
candidates. Such statements are based on management’s current
expectations, but actual results may differ materially due to
various risks and uncertainties, including, but not limited to the
risks related to Cytokinetics’ business outlines in Cytokinetics’
filings with the Securities and Exchange Commission.
Forward-looking statements are not guarantees of future
performance, and Cytokinetics’ actual results of operations,
financial condition and liquidity, and the development of the
industry in which it operates, may differ materially from the
forward-looking statements contained in this press release. Any
forward-looking statements that Cytokinetics makes in
this press release speak only as of the date of this press
release. Cytokinetics assumes no obligation to update its
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
CYTOKINETICS® and the C-shaped logo are registered trademarks of
Cytokinetics in the U.S. and certain other countries.
Contact:CytokineticsDiane
WeiserSenior Vice President, Corporate Communications, Investor
Relations(415) 290-7757
Cytokinetics (NASDAQ:CYTK)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Cytokinetics (NASDAQ:CYTK)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024